How effective is ivonib in treating cholangiocarcinoma?

Ivosidenib (Ivosidenib) is a targeted therapy drug that targets specific gene mutations in certain patients with cholangiocarcinoma. This drug blocks the growth and spread of tumor cells by inhibiting the abnormal enzyme activity produced by IDH1 gene mutations. Current clinical studies show that ivonib has certain efficacy in the treatment of patients with cholangiocarcinoma with specific gene mutations.

Ivonib was investigated in a major study involving 187 adults with biliary tract cancer that had spread or was unresectable with surgery and who had received at least one prior systemic therapy. All patients had IDH1 R132 mutations. Patients taking ivonib survived an average of 2.7 months without disease progression and 10.3 months overall, compared with 1.4 months and 7.5 months for those taking placebo, respectively. In this study, 52% of patients who received ivonib experienced worsening and 10% died, compared with 72% (44 of 61 patients) and 10% (6 patients) of the placebo group.

The original version of ivonib has been launched in China, but it is not covered by medical insurance. The price of domestically sold specifications0.25g*60 tablets per box is as high as 100,000 yuan, while the price of the original American version sold overseas is as high as more than 200,000 yuan per box (the price may fluctuate due to exchange rates). Generic drugs of Ivonib are also sold overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Laos pharmaceutical factory may be more than 6,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.